A thyroid pill recall gets the FDA’s most serious rating because one lot may be too strong

One lot of Thyroid Tablets, USP 30 mg made by Vitruvias Therapeutics of Alabama now carries the FDA’s most serious recall rating. The agency classified the recall as Class One on September 22, 2026, weeks after the company announced on August 21 that testing had confirmed the tablets could be superpotent, meaning stronger than the label says. Only lot 504950 is involved, and it expires September 30, 2026.

The recall matters mostly to people who take desiccated thyroid, a prescription extract used to treat an underactive thyroid. The company and the FDA give one instruction that runs against instinct: do not quit the medicine on the spot.

Lot 504950 and the numbers behind it

According to the recall announcement posted on the FDA website, the affected product is Thyroid Tablets, USP 30 mg, NDC 69680-166-00, lot 504950, packed in 100-count bottles. Vitruvias reported that 3,655 units were released and 1,955 were sold, with distribution nationwide. The tablets shipped between January 31 and September 30, 2025, the window the company reported for the lot.

The stated reason is a single laboratory finding. Testing confirmed the potential for the product to be superpotent, the company said, which means patients could receive more thyroid hormone per tablet than the label promises. The notice described no other manufacturing defect, no contamination and no wider set of lots, and it is the only lot named for recall.

The medicine at issue is what the Epoch Times described as a natural preparation derived from porcine thyroid glands, composed of levothyroxine and liothyronine.

From voluntary recall to Class One rating

Recalls are sorted into three classes by severity, and Class One is the top tier. Reporting on the classification, which cited the FDA, said the rating applies where use of or exposure to the product could cause serious adverse health consequences or death. Quartz reported that the agency assigned the Class One designation on September 22, and News4Jax gave the same classification date and put the volume at 1,955 bottles.

The timing is easy to misread. The recall itself was voluntary and announced by the company on August 21, and KTBS reported an initial recall date of August 24, 2026. The classification is the FDA’s own after-the-fact judgment about how dangerous the problem is, and it followed a month later. Nothing in the reporting says the lot was changed, expanded or re-tested in between.

The severity rating reflects the risk of the drug class rather than any confirmed harm from this lot. The company reported no adverse events tied to the tablets as of August 21, and KTBS repeated that no reactions had been reported when the recall was announced. A Class One label can therefore coexist with zero known injuries, because it measures what could reasonably happen if the pills are too strong, not what has been documented. The gap between those two things is why the FDA’s rating and the company’s zero-reports statement can both be accurate at once, and why patients holding a bottle from this lot are still asked to act.

Symptoms the company lists, and who is most exposed

Excess thyroid hormone can produce hyperthyroidism. Vitruvias listed the possible effects as “weight loss, heat intolerance, fatigue, nervousness, muscle weakness, hypertension, chest pain, rapid heart rate, or heart rhythm disturbances.” The list runs from the merely unpleasant to the cardiac. The notice singles out three groups as most vulnerable: elderly patients, pregnant women and infants. In infants, the announcement said, overtreatment can have negative effects on growth and development. News4Jax added that people with heart conditions or sensitivity to thyroid hormone face particular danger from extra hormone.

Patients taking this lot are told not to discontinue use without contacting their healthcare provider. The company can be reached at (256) 239-9373, Monday through Friday, 9 a.m. to 5 p.m. Central time, or at [email protected], and the FDA’s MedWatch program takes adverse-event reports at 1-800-332-1088. One local report says to stop using the product immediately, which conflicts with the company and FDA notice; the notice, not the summary, is the controlling instruction.

A recall on the opposite side of the dose

Thyroid tablets have been recalled for missing their dose target before, in the other direction. In September 2020, Acella Pharmaceuticals recalled two lots of NP Thyroid after testing found them sub potent, with as little as 87 percent of the labeled levothyroxine. Its recall notice warned of fatigue, cold sensitivity and weight gain, and said the company had received four reports of adverse events possibly related to those lots.

Still unknown is how much of lot 504950 is still in medicine cabinets. Of the 3,655 units the company released, 1,955 were sold, and the lot has a September 30, 2026 expiry date. Vitruvias has not published how much of the product patients have already used, and the FDA classification does not say.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview